VYNE Therapeutics (VYNE) Assets Average (2018 - 2026)

VYNE Therapeutics' Assets Average history runs 9 years deep, the most recent figure standing at $28.0 million for Q1 2026.

• Quarterly Assets Average fell 54.57% year-over-year to $28.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.0 million (down 54.57% YoY) and the FY2025 annual result came in at $48.5 million, down 41.03% from the prior year.
• Assets Average was $28.0 million for Q1 2026 at VYNE Therapeutics, down from $37.4 million in the prior quarter.
• Across five years, Assets Average topped out at $94.7 million in Q1 2024 and bottomed at $22.1 million in Q3 2023.
• A 5-year average of $55.2 million and a median of $54.8 million in 2022 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2022 — Assets Average plunged 57.79% — and 2024, when it jumped 268.21%.
• VYNE Therapeutics' Assets Average stood at $43.8 million in 2022, then soared by 33.41% to $58.5 million in 2023, then climbed by 22.36% to $71.6 million in 2024, then plunged by 47.68% to $37.4 million in 2025, then declined by 25.17% to $28.0 million in 2026.
• Business Quant data shows VYNE's Assets Average at $28.0 million in Q1 2026, $37.4 million in Q4 2025, and $50.6 million in Q2 2025.